Perftoran therapy perspectives in reperfusion syndrome prevention among acute myocardial infarction patients

Abstract

In spite of recent achievements in Q-wave myocardial infarction (Q-IM) management, prevention of reperfusion syndrome, developing due to coronary artery opening in thrombolytic therapy (TLT), is still an unsolved problem. Aim. To assess the incidence of reperfusion syndrome and its manifestations, cardiac arrhythmias and recurrent pain syndrome attacks, in Q-IM patients treated with perftoran. Material and methods. In total, 166 Q-IM patients were examined and treated. All participants received TLT; 46 individuals also received perftoran. The incidence of cardiac arrhythmias and recurrent pain syndrome attacks was assessed. Results. In Q-IM patients, perftoran and TLT reduced reperfusion syndrome incidence by 26.8%, ventricular extrasystolia incidence – by 24.2%, and sinus bradycardia – by 17.3%; no ventricular fibrillation cases were registered. Moreover, perftoran decreased recurrent pain syndrome attack incidence. Conclusion. Perftoran beneficially influenced clinical course of reperfusion syndrome in Q-IM. Perftoran could be included into Q-IM complex therapy.

Keywords

• q-образующий инфаркт миокарда
• тромболитическая терапия
• реперфузионный синдром
• перфторан